This Special Communication discusses the Food and Drug Administration’s (FDA’s) proposed rule that would limit N-nitrosonornicotine (NNN) levels in smokeless tobacco products. It argues that finalising and implementing this first ’product standard' would mark a significant step forward in the FDA’s efforts to reduce tobacco-related harms.
- public policy
- Non-cigarette tobacco products
- harm reduction
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Contributors The authors contributed equally to the development of this article.
Funding Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Numbers U19CA157345 and K07CA197221.
Disclaimer The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Correction notice This paper has been amended since it was published Online First. Owing to a scripting error, some of the publisher names in the references were replaced with ’BMJ Publishing Group'. This only affected the full text version, not the PDF. We have since corrected these errors and the correct publishers have been inserted into the references.